Скачать или смотреть Revolutionizing Respiratory Care with Inspira Technologies $IINN

This Nasdaq Biotech Micro Cap might be on the verge of revolutionizing a 19B Dollar Industry. #IINN $IINN#shortsqueeze #investing #inspira #Nasdaq #Microcap #Smallcap #Stock #stockmarket #growthstocks #stockmarkettips #Wallstreet #stockstobuy

Inspira Technologies (NASDAQ: IINN)* is challenging the $19 billion mechanical ventilation industry with a revolutionary approach: delivering oxygen directly to the blood instead of forcing air into damaged lungs. Their breakthrough could allow respiratory patients to remain awake during treatment—no tubes, no comas.

With their FDA-cleared INSPIRA ART100 system now treating real patients at a leading New York hospital and generating first revenues, Inspira is moving from concept to clinical reality. Their HYLA blood sensor recently achieved 96% accuracy in clinical trials, while their flagship INSPIRA ART500 system in development aims to disrupt a market plagued by 50%+ mortality rates.

As the medtech acquisition landscape heats up ($21+ billion in recent deals), Inspira’s technology for the 20 million annual ICU respiratory patients could represent significant breakthrough potential.

*Disclaimer: Nothing in this content constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This content was not reviewed by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: http://redditwire.com/terms. Readers are advised to refer to the full news releases mentioned and or linked and the issuers full financial and regulatory filings. This post is shared as part of Inspira's paid distribution agreement with us.